View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
May 5, 2011

MicroPulse Treatment Effective Against Diabetic Macular Oedema

Iridex Corporation has announced the benefits of MicroPulse photocoagulation technology over the standard-of-care treatment for diabetic macular oedema retinal damage caused by diabetes. MicroPulse technology is a tissue-sparing laser emission that "chops" laser trains into microsecond

By cms admin

Iridex Corporation has announced the benefits of MicroPulse photocoagulation technology over the standard-of-care treatment for diabetic macular oedema retinal damage caused by diabetes.

MicroPulse technology is a tissue-sparing laser emission that “chops” laser trains into microsecond pulses, which enhances the potential for ocular treatment options with greater efficiency and with less collateral effects.

The randomised, controlled and double-masked clinical study involved 123 patients and showed that the device was effective in improving visual acuity with the added advantages of causing no localised laser scars.

Iridex president and CEO Theodore Boutacoff said, “This is the first study to demonstrate a significant improvement in best corrected visual acuity using subthreshold diode laser MicroPulse treatment compared to the standard laser photocoagulation treatment of diabetic macular oedema.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management